アブストラクト
| Title | 減塩指導下でのSGLT2阻害薬の投与が及ぼす1日食塩摂取量および腎機能への影響 |
|---|---|
| Subtitle | 論文 原著論文 |
| Authors | 篠原正樹1, 田野岡健1, 谷崎文彦1, 中村達2 |
| Authors (kana) | |
| Organization | 1医療法人住友別子病院薬剤部, 2糖尿病内科 |
| Journal | 日本病院薬剤師会雑誌 |
| Volume | 58 |
| Number | 1 |
| Page | 41-46 |
| Year/Month | 2022 / 1 |
| Article | 原著 |
| Publisher | 日本病院薬剤師会 |
| Abstract | ナトリウム・グルコース共役輸送体2(sodium glucose co-transporter type 2:SGLT2)阻害薬と1日食塩摂取量との関連は明確ではない. 本研究では, 減塩指導下で1日食塩摂取量を測定した糖尿病患者のうち本薬を6カ月以上投与した89症例に対して, 12カ月間の観察研究を実施し, 観察開始時および終了後のグリコヘモグロビン(glycohemoglobin A1c:以下, HbA1c), 1日食塩摂取量, 推定糸球体濾過量(estimated glomerular filtration rate:以下, eGFR)を比較した. また, 本薬投与初期にeGFRの低下を起こすhyperfiltrationとの関連についても検討を行った. Hyperfiltrationの有無では, 12カ月後のeGFRに有意差はなかった. 本研究の観察期間では, 観察終了後にeGFRは保持(p=0.752)されており, 減塩指導下で本薬を投与することにより1日食塩摂取量は減少し(p=0.013), 体重の減少を伴うことでHbA1cの改善(p=0.039)が得られ, 腎機能の保護に繋がると考えられた. |
| Practice | 薬学 |
| Keywords | SGLT2阻害薬, eGFR, 1日食塩摂取量, 減塩指導, hyperfiltration |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) 一般社団法人日本透析医学会 : わが国の慢性透析療法の現況, 2018年12月31日. https://docs.jsdt.or.jp/overview/index.html, 2020年12月10日参照
- 2) S Kohler, C Zeller, H Iliev, S Kaspers : Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes : Pooled Analysis of Phase I-III Clinical Trials,Advances in Therapy, 34, 1707-1726 (2017).
- 3) T Shiba, S Ishii, T Okamura, R Mitsuyoshi, E Pfarr, K Koiwai : Efficacy and safety of empagliflozin in Japanese patients with type 2 diabetes mellitus : A sub-analysis by body mass index and age of pooled data from three clinical trials, Diabetes Res Clin Pract, 131, 169-178 (2017).
- 4) K Yokote, Y Terauchi, I Nakamura, H Sugamori :Realworld evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLAELDER) : final results of a post-marketing surveillance study, Expert Opin Pharmacother, 17, 1995-2003 (2016).
- 5) AJ Sinclair, B Bode, S Harris, U Vijapurkar, W Shaw, M Desai, G Meininger : Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus : A Pooled Analysis, J Amer Geriat Soc, 64, 543-552 (2016).
残りの11件を表示する
- 6) C Wanner, SE Inzucchi, B Zinman : Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes, N Engl J Med, 375, 323-334 (2016).
- 7) B Neal, V Perkovic, KW Mahaffey, D de Zeeuw, G Fulcher, N Erondu, W Shaw, G Law, M Desai, DR Matthews :Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes, N Engl J Med, 377, 644-657 (2017).
- 8) DZI Cherney, B Zinman, SE Inzucchi, AK Weber, M Mattheus, M von Eynatten, C Wanner : Effect of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type2 diabetes and established cardiovascular disease : an exploratory analysis from the EMPA-REG OUTCOME randomized, placebo-controlled trial, Lancet Diabetes Endocinol, 5, 610-621 (2017).
- 9) K Nunoi, Y Sato, K Kaku, A Yoshida, H Suganami : Renal effects of a sodium-glucose cotransporter 2 inhibitor,tofogliflozin, in relation to sodium intake and glycaemic status, Diabetes Obes Metab, 21, 1715-1724 (2019).
- 10) BJ Kraus, MR Weir, GL Bakris, M Mattheus, DZI Cherney,N Sattar, HJL Heerspink, I Ritter, M von Eynatten, B Zinman,SE Inzucchi, C Wanner, A Koitka-Weber : Characterization and implications of the initial estimated glomerular filtration rate `dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial, Kidney Int, 99, 750-762 (2020).
- 11) KW Mahaffey, B Neal, V Perkovic, D de Zeeuw, G Fulcher, N Erondu, W Shaw, E Fabbrini, T Sun, Q Li, M Desai, DR Matthews : Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events : Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study), Circulation, 137, 323-334 (2017).
- 12) DZI Cherney, BA Perkins : Sodium-glucose cotransporter 2 inhibition in type 1 diabetes : simultaneous glucose lowering and renal protection?, Can J Diabetes, 38,356-363 (2014).
- 13) MJ Klag, PK Whelton, BL Randall, JD Neaton, FL Brancati, CE Ford, NB Shulman, J Stamler : Blood pressure and end-stage renal disease in men, N Engl J Med, 334,13-18 (1996).
- 14) T Tanaka, T Okamura, K Miura, T Kadowaki, H Ueshima,H Nakagawa, T Hashimoto : A simple method to estimate populational 24-h urinary sodium and potassium excretion using a casual urine specimen, J Hum Hypertens,16, 97-103 (2002).
- 15) Y Kanda : Investigation of the freely available easy-touse software 'EZR' for medical statistics, Bone Marrow Transplant, 48, 452-458 (2013).
- 16) V Perkovic, MJ Jardine, B Neal, S Bompoint, HJL Heerspink, DM Charytan, R Edwards, R Agarwal, G Bakris,S Bull, CP Cannon, G Capuano, PL Chu, D de Zeeuw, T Greene, A Levin, C Pollock, DC Wheeler, Y Yavin, H Zhang,B Zinman, G Meininger, BM Brenner, KW Mahaffey ;CREDENCE Trial Investigators : Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy, N Engl J Med, 380, 2295-2306 (2019).
